Ensemble Therapeutics achieves early-stage research milestone in drug discovery collaboration with Alexion

Under the terms of the agreement, Ensemble is applying its drug discovery platform against several Alexion targets to discover new small molecule clinical candidates. Alexion will have exclusive worldwide rights to develop and commercialize candidates arising from the collaboration.

"Achievement of this milestone provides additional validation of our proprietary drug discovery platform and our macrocycle development efforts," said John Ripple, chief executive officer of Ensemble.

"We are pleased our collaboration with Alexion continues to progress and look forward to further advancing our productive partnership."

Ensemble is harnessing its exclusive drug discovery methodology to develop synthetic macrocycles and other novel small molecules that expand the boundaries of traditional therapeutics.

With extensive expertise in cancer therapeutics, Ensemble is focused on high value targets within the immune checkpoint and ubiquitin proteasome system.

Added Mr. Ripple, "While partnering is a core component of our business strategy, we are also developing a growing internal pipeline of therapeutic candidates to treat cancer and other serious diseases, including programs that target IDO and USP9x."